Verici Dx plc (AIM:VRCI)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 7.95M +13.0% |
| Revenue (ttm) | 1.40M -55.9% |
| Net Income | -5.56M |
| EPS | -0.02 |
| Shares Out | 1.51B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,770,484 |
| Average Volume | 1,583,384 |
| Open | 0.5000 |
| Previous Close | 0.5200 |
| Day's Range | 0.5000 - 0.5400 |
| 52-Week Range | 0.4450 - 2.5000 |
| Beta | 1.40 |
| RSI | 50.22 |
| Earnings Date | Apr 21, 2026 |
About Verici Dx
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. It also offers sequencing services for tumor-only, tumor-normal, and germline exomes; whole transcriptome, targeted RNASeq and ncRNAs, and functiona... [Read more]
Financial Performance
In 2024, Verici Dx's revenue was $3.34 million, an increase of 229.62% compared to the previous year's $1.01 million. Losses were -$5.87 million, -32.75% less than in 2023.
Financial numbers in USD Financial StatementsNews
FBB Biomed Signs Agreement with Verici Dx plc to Offer Research-Use-Only “RUO” Tests to Clinicians
CORALVILLE, Iowa--(BUSINESS WIRE)--FBB Biomed today announced it has signed a Master Services Agreement with Verici Dx plc (AIM: VRCI.L), for Laboratory Services for Research-Use-Only (RUO) (FDA defin...